NCT07496515 (CH01) is a Phase 2 clinical trial of Omega-3 supplement in Pediatric Chalazia, sponsored by Jaeb Center for Health Research.

Who is sponsoring NCT07496515?

NCT07496515 is sponsored by Jaeb Center for Health Research.

What drugs are being tested in NCT07496515?

Interventions in NCT07496515: Omega-3 supplement, Warm compress, Standard eyelid cleanser, Anti-Demodex eyelid cleanser.

What condition does NCT07496515 study?

NCT07496515 studies Pediatric Chalazia.

Is NCT07496515 still recruiting?

NCT07496515 is currently not yet recruiting. Last updated 27 March 2026.

Last reviewed 2026-03-27 · How we verify

NCT07496515: CH01

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Omega-3 Supplementation vs Demodex vs Eyelid Cleanser for Pediatric Chalazia

Not yet recruiting Phase 2 Last updated 27 March 2026

What this trial tests

Phase 2 trial testing Omega-3 supplement in Pediatric Chalazia in 168 participants. Not yet recruiting.

Timeline

1 June 2026

Primary endpoint
1 August 2026

1 February 2028

Quick facts

Lead sponsor	Jaeb Center for Health Research
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	168
Start date	1 June 2026
Primary completion	1 August 2026
Estimated completion	1 February 2028

Drugs / interventions tested

Omega-3 supplement — full drug profile →
Warm compress
Standard eyelid cleanser
Anti-Demodex eyelid cleanser

Conditions studied

Pediatric Chalazia — all drugs for Pediatric Chalazia →

Sponsor

Jaeb Center for Health Research — full company profile →

Who can join

Adults 4 to 17, any sex, with Pediatric Chalazia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Participants enrolled into the study will be prescribed twice daily warm compresses for 8 weeks and randomly allocated (1:1:1) to receive either 1) Oral omega-3 supplementation and standard eyelid cleanser, 2) Anti-Demodex eyelid cleanser, or 3) Standard eyelid cleanser as treatment for chalazia. Participants will return for a visit after 8 weeks for a masked clinical exam to determine whether the chalazia has improved or resolved. The 8-week visit will also include a masked central reader's assessment of parent photographs, parental palpation of eyelids, and review of Parental Treatment Outcome Question as part of a telehealth objective. After the 8-week visit, treatment is at investigator discretion other than 1) the OMEGA-3 group must continue the study-prescribed omega-3 supplementation and 2) the ANTI-DEMODEX and STANDARD groups must not receive omega-3 supplementation. Participants will be followed from 8 weeks to 12 months from baseline to determine the proportion of participants with new chalazia based on monthly parental report and office visits at 6 months and 12 months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Omega-3 supplement

Trials testing the same drug.

NCT03444662 — The Combination Effect of Citicoline and Omega-3 · NA · completed
NCT02021669 — Omega-3 for Depression and Other Cardiac Risk Factors - 2 · Phase 2 · completed

Other Jaeb Center for Health Research trials

Trials by the same sponsor.

NCT07095894 — A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control · Phase 3 · not yet recruiting
NCT06837181 — Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM) · recruiting
NCT06880835 — Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automate · NA · recruiting
NCT06957028 — CGM for the Early Detection and Management of Hyperglycemia in Pregnancy · NA · recruiting
NCT06524882 — Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07496515 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jaeb Center for Health Research
Last refreshed: 27 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07496515.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing